CJM-112

CJM-112 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A) . CJM-112 is promising for research of inflammatory diseases, such as hidradenitis suppurativa associated with abnormal IL-17A-related pathways[1].

Product Specifications

UNSPSC

12352203

Target

Interleukin Related

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

[CJM-112]

References & Citations

[1]Maarouf M, et al. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatolog Treat. 2018 Aug;29 (5) :441-449.|[2]Maarouf M, et al. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatolog Treat. 2018 Aug;29 (5) :441-449.